NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 18-cv-00646, is on behalf of a class consisting of investors who purchased or otherwise acquired Xunlei securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Xunlei securities between October 10, 2017, and January 11, 2018, both dates inclusive, you have until March 20, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Xunlei is a cloud-based acceleration technology company operating an internet platform in China based on cloud technology to enable users to access, manage, and consume digital media content. The Company’s main product is OneCloud, a network linked storage device allowing multiple users to share online storage remotely and a “mining machine” for users to share their idle bandwidth with Xunlei’s content delivery networks.

On October 10, 2017, Xunlei issued a press release announcing the introduction of “OneCoin”, a blockchain-based product with no central bank endorsed value. OneCoin was subsequently renamed “Lianke”.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Xunlei had engaged in an unlawful financial activity; (ii) OneCoin was a form of disguised initial coin offering (“ICO”); (iii) Xunlei was engaged in the promotion of an Initial Miner Offering (“IMO”); and (iv) as a result of the foregoing, Defendants’ statements about Xunlei’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On or about November 24, 2017, various news outlets in China reported that Xunlei’s business partner Shenzhen Xunlei Big Data Information Services Company Ltd. (“Big Data”) was accusing Xunlei of conducting an unlawful ICO through the Company’s OneCoin project.

On this news and over the course of two trading days, the Company’s ADS price declined $6.33 from a close on November 24, 2017, at $24.91 per ADS, to a close at $18.58 per ADS on November 28, 2017, a drop of approximately 25.41%.

On November 29, 2017, Xunlei issued a press release entitled “Xunlei Provides Clarification on Recent Market Development,” announcing an update on its business relationship with Big Data. The press release stated, in part, that Xunlei has requested Big Data to stop using the “Xunlei” brand name immediately and also terminated its right to use the “Xunlei” brand.

On this news, the Company’s ADS price declined $5.78 from a close on November 28, 2017, at $18.58 per ADS, to a close at $12.80 per ADS on November 29, 2017, a drop of approximately 31.1%.

On January 12, 2018, the National Internet Finance Association of China issued a “Risk Alert” notice regarding “Disguised ICO [Initial Coin Offering] Activities” (the “Risk Alert Notice”). The Risk Alert Notice referenced a September 2017 notice issued jointly by seven government ministries, which stated, in part, that “ICO activities are suspected of involving illegal criminal activities including illegal fund-raising, illegal issuance of securities, and illegal sale of notes and bonds” and “all institutions and individuals should immediately stop engaging in ICO activities.” The Risk Alert Notice further stated that “[i]n the case of Lianke issued by Xunlei . . . the issuing company in effect substitutes Lianke for the duty to pay back project contributors with legal tender, making it essentially a financing activity and a form of disguised ICO.”

On this news, the Company’s ADS price declined $6.27 from a close on January 11, 2018, at $22.90 per ADS, to a close at $16.63 per ADS on January 12, 2018, a drop of approximately 27.38%.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 487499

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Dr. Joel Singer, director of Park Avenue Stem Cell (PASC) announced online recently that he is currently investigating the benefits of using fat-derived adult stem cells harvested from a person’s own fat. He is an affiliate of the Cell Surgical Network, an international organization of physicians who are all involved in clinical research of this nature.

Dr. Singer graduated from the Yale School of Medicine. He has been practicing as a plastic surgeon for over 30 years and enjoys staying at the cutting edge of regenerative medicine. He works together with a network of many other specialists to treat patients with chronic conditions.

Stem cell therapy has provoked much controversy over the past decade, particularly with the use of embryonic stem cells. The ethical outcry created a negative impression about stem cell therapy. Bone marrow transplants are regularly used but there are limitations attached to their use. This has prompted researchers to look at other sources of stem cells.

Dr. Joel Singer is one of the surgeons using the mesenchymal stem cells found in a person’s own fat. New tools exist that allow stem cells to be separated from fat. The fat cells are harvested under local anesthesia and once they are injected into the patient, have the potential to form new cells and repair tissue.

One of the advantages of these stem cells is that they are abundant. There is no need to culture cells over a number of days. The liposuction type of harvesting is minimally invasive and cells can be deployed into the patient not long after harvesting.

The stem cells can be injected into different areas, depending on what type of treatment is required. They can be injected through arteries and veins, into the spinal fluid and even into joints and organs. They migrate to the areas of tissue damage and have the potential to regenerate them.

It is going to be some time before sufficient scientific data is collected to support anecdotal and experimental evidence of the efficacy of this type of treatment. In the interim, patients suffering from many forms of degenerative diseases are prepared to take part in experimental tests. Excellent safety data has been shown with the use of this type of therapy. These patients are treated with high numbers of adipose-derived stem cells.

Two unnamed patients currently undergoing regenerative stem cell therapy with Dr. Singer are ex-NFL football players. This is interesting in the light of the controversy surrounding the link between degenerative brain disease and football. The NFL has long skirted the issue of the damage to player’s health but bad publicity is forcing them to re-examine their protocols and do more to protect their players.

As the date for the Super Bowl draws closer, football fans look forward to the occasion. The thought of long-term consequences of head injuries to the players diminishes in the excitement surrounding the event. However, JoelSinger MD warns that concussions are one of the biggest ongoing problems faced by the NFL. The thought that some solutions may exist in the field of regenerative cell therapy is an encouraging one.

Joel Singer MD
Park Avenue Stem Cell
info@parkavenuestemcell.com
844-903 PARK (7275)
346 E 51st St. NY, NY 10022

SOURCE: Dr. Joel Singer MD

ReleaseID: 487501

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Aerohive Networks, Inc. (“Aerohive” or the “Company”) (NYSE: HIVE) and certain of its officers. The class action, filed in United States District Court, for the Northern District of California, and docketed under 18-cv-00544, is on behalf of a class consisting of investors who purchased or otherwise acquired Aerohive securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Aerohive securities between November 1, 2017, and January 16, 2018, both dates inclusive, you have until March 20, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Aerohive supplies wireless infrastructure equipment. The Company designs cooperative control wireless architecture, cloud-enabled network management, routing, and virtual private network solutions. Aerohive serves the healthcare, education, manufacturing, distribution, and retail industries throughout the United States.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Aerohive had uncovered sales execution issues at the Company at the end of the third quarter of 2017; (ii) consequently, Aerohive’s revenue guidance for the fourth quarter of 2017 was overstated; and (iii) as a result, Aerohive’s public statements were materially false and misleading at all relevant times.

On January 16, 2018, post-market, Aerohive issued a press release entitled “Aerohive Networks Announces Preliminary Fourth Quarter 2017 Financial Results,” revealing that it “expects net revenue for the fourth quarter to be approximately $37 million, which is below the Company’s previously stated guidance of $40 million to $42 million.” Aerohive attributed the reduced guidance to “underlying sales execution issues” uncovered at the end of the third quarter.

On this news, Aerohive’s share price fell $1.63, or 28.6%, to close at $4.07 on January 17, 2018, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 487498

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Pomerantz LLP and Levi & Korsinsky, LLP announce that the United States District Court for the Northern District of Ohio has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of TCP International Holdings, Ltd. (OTC PINK: TCPIF):

SUMMARY NOTICE OF PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT, SETTLEMENT FAIRNESS HEARING, AND MOTION FOR AWARD OF ATTORNEYS’ FEES AND REIMBURSEMENT OF LITIGATION EXPENSES

TO: All Persons who purchased or otherwise acquired TCP International Holdings Ltd. (”TCPI”) common stock (ticker symbol: TCPI) on the public market between May 9, 2015 and November 5, 2015 (the ”Class Period”), inclusive, and were damaged thereby.

EXCLUDED FROM THE CLASS ARE DEFENDANTS, THE OFFICERS AND DIRECTORS OF TCPI, AND THEIR FAMILIES AND AFFILIATES.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Northern District of Ohio, that a hearing will be held on February 1, 2018 at 10:00 a.m., before the Honorable Donald C. Nugent, United States District Judge, in Courtroom 15A of the United States District Court for the Northern District of Ohio, Carl B. Stokes United States Court House, 801 West Superior Avenue, Cleveland, Ohio, to determine: (1) whether a Settlement Class should be certified for purposes of the Settlement and whether Lead Plaintiff and its counsel have adequately represented the Class Members; (2) whether the proposed Settlement of the Class’s claims against the Defendants for $1,100,000.00 should be approved as fair, reasonable and adequate; (3) whether the proposed Plan of Allocation is fair, just, reasonable, and adequate; (4) whether the Court should permanently enjoin the assertion of any claims that arise from or relate to the subject matter of the Action; (5) whether the Action should be dismissed with prejudice against the Defendants as set forth in the Stipulation of Settlement filed with the Court; (6) whether the application by Lead Counsel for an award of attorneys’ fees and expenses should be approved; and (7) whether an application for reimbursement of costs and expenses of Lead Plaintiff members should be granted.

If you purchased or otherwise acquired TCPI common stock trading under ticker symbol TCPI during the Class Period, your rights may be affected by this Action and the Settlement thereof. You may obtain a detailed Notice of Pendency of Class Action and Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys’ Fees and Reimbursement of Litigation Expenses (the ”Notice”) and Proof of Claim and Release Form, free of charge by contacting the Claims Administrator, by mail at: TCP Int’l Litigation, c/o Strategic Claims Services, P.O. Box 230, 600 N. Jackson Street, Suite 3, Media, PA 19063; by telephone at: 866-274-4004; or by visiting the website at: www.strategicclaims.net/TCP.

If you are a member of the Class and wish to share in the Settlement money, you must submit a Proof of Claim postmarked no later than March 5, 2018 establishing that you are entitled to recovery. As further described in the Notice, you will be bound by any judgment entered in the Action, regardless of whether you submit a Proof of Claim, unless you exclude yourself from the Class, in accordance with the procedures set forth in the Notice, postmarked by no later than January 12, 2018. Any objections to the Settlement, Plan of Allocation or attorney’s fees and expenses must be filed, in accordance with the procedures set forth in the Notice, to be received no later than January 12, 2018.

Inquiries, other than requests for the Notice, may be made to Lead Counsel for the Class: Leigh Handelman Smollar, Pomerantz LLP, 10 South La Salle Street, Ste. 3505, Chicago, IL 60603, Telephone: 312-377-1181.

INQUIRIES SHOULD NOT BE DIRECTED TO THE COURT, THE CLERK’S OFFICE, THE DEFENDANTS, OR DEFENDANTS’ COUNSEL

DATED: JULY 28, 2017 BY ORDER OF THE UNITED STATES

DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 487495

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Wynn Resorts, Limited (”Wynn” or the ”Company”) (NASDAQ: WYNN). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/wynn.

The investigation concerns whether Wynn and certain of its officers and/or directors have violated Federal Securities Laws.

On January 26, 2018, The Wall Street Journal published a report stating that ”[d]ozens of people The Wall Street Journal interviewed who have worked at Mr. Wynn’s casinos told of behavior that cumulatively would amount to a decades-long pattern of sexual misconduct by Mr. Wynn. Some described him pressuring employees to perform sex acts.” Following this news, Wynn stock dropped $20.31 per share or roughly over 10% to close at $180.29 per share on January 26, 2018.

If you are aware of any facts relating to this investigation, or purchased Wynn shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/wynn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 487494

LOS ANGELES, CA / ACCESSWIRE / January 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Acuity Brands, Inc. (”Acuity” or ”the Company”) (NYSE: AYI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between June 29, 2016 and April 3, 2017, inclusive (the ”Class Period”), are encouraged to contact the firm before March 5, 2018, the lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the lawsuit, the Company made materially false and/or misleading statements and/or failed to disclose that: (1) known trends were negatively impacting sales of Acuity’s products; (2) Acuity’s ability to achieve profitable sales growth was overstated; and (3) as a result, defendants’ positive statements about Acuity’s current and future business and financial prospects lacked a reasonable basis. Following this news, the Company’s stock price fell materially, which caused investors harm.

The Schall Law Firm represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
Schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 487410

NEW YORK, NY / ACCESSWIRE / January 31, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Credit Suisse Group A.G. (”Credit Suisse” or the ”Company”) (NYSE: CS) and certain of its officers, on behalf of shareholders who purchased Credit Suisse securities between March 20, 2015 through February 3, 2016, both dates inclusive (”Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/cs.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that Defendants made false and/or misleading statements and failed to disclose that: (1) Credit Suisse’s risk protocols and control systems were routinely disregarded; (2) Credit Suisse was amassing billions of dollars of risky, highly illiquid securities, in violation of those risk protocols; and (3) consequently, defendants’ statements about Credit Suisse’s business, operations, and risk controls were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/cs or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Credit Suisse you have until February 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 485246